Trump’s Executive Order Fast-Tracks Psychedelic Drugs, Raising Questions About Safety and Oversight

On April 18, 2026, President Donald Trump signed an executive order titled Accelerating Medical Treatments for Serious Mental Illness, directing federal agencies to fast-track psychedelic drugs as potential treatments for conditions like treatment-resistant depression and PTSD. This marks a significant shift in federal drug policy, moving psychedelics from Schedule I status—meaning no accepted medical use and high abuse potential—to prioritized candidates for expedited FDA review and research funding.

The order aims to address what the administration calls a “crisis of serious mental illness,” citing statistics that 15.4 million adults in the U.S. suffer from such conditions and that existing treatments often fail or are inaccessible. The directive instructs the FDA to grant priority review vouchers to psychedelic drugs with Breakthrough Therapy designation and encourages use of the Right to Try Act to allow patients access to investigational psychedelics, including controversial compounds like ibogaine.

Within days, the FDA issued priority vouchers for three psychedelic programs, including psilocybin for depression and methylone for PTSD. However, this rapid elevation surprised many experts, especially since the FDA had previously rejected similar MDMA-assisted therapies. The administration also pledged $50 million through ARPA-H to support state partnerships advancing psychedelic research.

While proponents argue this could revolutionize mental health treatment, critics warn the order sidesteps rigorous scientific validation and regulatory oversight, potentially exposing vulnerable patients to unproven and risky substances. The Trump administration’s eagerness to accelerate psychedelic drug development fits a broader pattern of executive overreach, undermining established processes designed to protect public health.

As psychedelics move closer to mainstream medical use under this directive, the urgent question remains: will speed come at the cost of safety and accountability? We will be watching closely as federal agencies implement this controversial policy shift.